This Stock Gets a Cut Every Time Big Pharma Sells a Shot #Halozyme #HALO #Stocks #Healthcare
1 extracted signal · 0 resolved · 1 still active
Inside Edge Capital | Todd GordonIndependent analyst profile- Source published
- 16 Oct 2026, 16:50 UTC
- Recorded by Tahlil Plus
- 22 Oct 2026, 15:45 UTC
AI-generated source summary
The analysis focuses on Halozyme Therapeutics (HALO), a biotech company. The stock has broken out to new highs, surpassing resistance and trading above its 50-day and 200-day moving averages. The company has demonstrated strong sales growth, increasing between 20% and 60% annually since 2019, and has generated approximately $4 per share in profit over the last two years. Halozyme Therapeutics recently won an injunction against Merck. The speaker views this not just as a value play but also as a growth story. The predicted target price for HALO is $11.00, with an expected timeframe within 2026. The failure bound for this bullish thesis is set at $8.84.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Inside Edge Capital | Todd Gordon
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.